{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:51:24Z","timestamp":1790790684197,"version":"4.1.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T00:00:00Z","timestamp":1683590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016469","name":"Takeda Pharmaceuticals International","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016469","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with inflammatory bowel disease (IBD), including Crohn\u2019s disease and ulcerative colitis, may develop extraintestinal manifestations (EIMs). The EMOTIVE study aimed to analyze the effect of vedolizumab on EIMs in a real-world cohort of patients with IBD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multicenter, descriptive, retrospective study was conducted in Belgium, Denmark, Israel, the Netherlands, and Switzerland in adults with moderately to severely active IBD and concurrent active EIMs at vedolizumab initiation (index date), with a \u22656-month follow-up after the index date. The primary endpoint was resolution of all EIMs within 6 months of vedolizumab initiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In 99 eligible patients, the most frequent EIMs were arthralgia (69.7%), peripheral spondyloarthritis (21.2%), and axial spondyloarthritis (10.1%). Within 6 and 12 months of vedolizumab initiation, 19.2% and 25.3% of patients reported resolution of all EIMs, while 36.5% and 49.5% of all EIMs were reported to be improved (combination of resolution and partial response), respectively. Vedolizumab treatment persistence at 12 months was 82.8%. Adverse events were reported in 18.2% of patients, with the most frequent being arthralgia (4.0%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This real-world study showed resolution of all EIMs in up to one-fourth of patients with IBD and improvement in up to half of EIMs within 12 months of vedolizumab treatment. Overall, vedolizumab was effective on EIMs in patients with IBD and showed a good safety profile.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izad075","type":"journal-article","created":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T20:24:08Z","timestamp":1683750248000},"page":"1713-1722","source":"Crossref","is-referenced-by-count":13,"title":["Impact of Vedolizumab on Extraintestinal Manifestations in Inflammatory Bowel Disease: Results From a Descriptive, Retrospective, Real-world Study"],"prefix":"10.1093","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7156-0588","authenticated-orcid":false,"given":"Uri","family":"Kopylov","sequence":"first","affiliation":[{"name":"Gastroenterology Institute, Sheba Medical Center, Tel HaShomer, Sackler School of Medicine , Tel Aviv University, Tel Aviv , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3312-5139","authenticated-orcid":false,"given":"Johan","family":"Burisch","sequence":"additional","affiliation":[{"name":"Gastrounit, Medical Division, Hvidovre Hospital, University of Copenhagen , Hvidovre , Denmark"},{"name":"Copenhagen Center for Inflammatory Bowel Disease in Children, Adolescents and Adults, Hvidovre Hospital, University of Copenhagen , Hvidovre , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shomron","family":"Ben-Horin","sequence":"additional","affiliation":[{"name":"Gastroenterology Institute, Sheba Medical Center, Tel HaShomer, Sackler School of Medicine , Tel Aviv University, Tel Aviv , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Braegger","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International AG , Z\u00fcrich , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alonso","family":"Fern\u00e1ndez-Nistal","sequence":"additional","affiliation":[{"name":"Takeda Farmac\u00e9utica Espa\u00f1a S.A., Medical Department , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Lara","sequence":"additional","affiliation":[{"name":"IQVIA, Real World Evidence Solutions , Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henriette Sophie","family":"Heinrich","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology, Clarunis\u2013Universit\u00e4res Bauchzentrum Basel , Basel , Switzerland"},{"name":"Department of Gastroenterology and Hepatology, University Hospital Z\u00fcrich , Z\u00fcrich , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan R","family":"Vavricka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Hospital Z\u00fcrich , Z\u00fcrich , Switzerland"},{"name":"Center for Gastroenterology and Hepatology AG , Z\u00fcrich , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,5,9]]},"reference":[{"issue":"2","key":"2023110711203627500_CIT0001","doi-asserted-by":"crossref","first-page":"113","DOI":"10.25122\/jml-2018-0075","article-title":"A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease","volume":"12","author":"Seyedian","year":"2019","journal-title":"J Med Life"},{"issue":"3","key":"2023110711203627500_CIT0002","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/ecco-jcc\/jjv213","article-title":"The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease","volume":"10","author":"Harbord","year":"2016","journal-title":"J Crohns Colitis"},{"issue":"Suppl 1","key":"2023110711203627500_CIT0003","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000341950","article-title":"Treatment of extraintestinal manifestations in inflammatory bowel disease","volume":"86","author":"Lakatos","year":"2012","journal-title":"Digestion."},{"issue":"Suppl 1","key":"2023110711203627500_CIT0004","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1159\/000502816","article-title":"Therapies in inflammatory bowel disease patients with extraintestinal manifestations","volume":"101","author":"Juillerat","year":"2020","journal-title":"Digestion."},{"issue":"4","key":"2023110711203627500_CIT0005","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1136\/gutjnl-2020-322129","article-title":"Emerging treatment options for extraintestinal manifestations in IBD","volume":"70","author":"Greuter","year":"2021","journal-title":"Gut."},{"issue":"4","key":"2023110711203627500_CIT0006","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1136\/gut.2005.074815","article-title":"Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial","volume":"55","author":"Brooklyn","year":"2006","journal-title":"Gut."},{"issue":"5","key":"2023110711203627500_CIT0007","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1093\/ecco-jcc\/jjy191","article-title":"The pathogenesis of extraintestinal manifestations: implications for IBD research, diagnosis, and therapy","volume":"13","author":"Hedin","year":"2019","journal-title":"J Crohns Colitis"},{"issue":"9","key":"2023110711203627500_CIT0008","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1177\/2050640620950093","article-title":"Assessment of extraintestinal manifestations in inflammatory bowel diseases: a systematic review and a proposed guide for clinical trials","volume":"8","author":"Guillo","year":"2020","journal-title":"United European Gastroenterol J"},{"key":"2023110711203627500_CIT0009","volume-title":"Prescribing Information","author":"Entyvio"},{"key":"2023110711203627500_CIT0010","volume-title":"Summary of Product Characteristics","author":"Entyvio"},{"issue":"12","key":"2023110711203627500_CIT0011","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/ecco-jcc\/jjw092","article-title":"An overview of the mechanism of action of the monoclonal antibody vedolizumab","volume":"10","author":"Wyant","year":"2016","journal-title":"J Crohns Colitis"},{"issue":"8","key":"2023110711203627500_CIT0012","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med."},{"issue":"8","key":"2023110711203627500_CIT0013","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N Engl J Med."},{"issue":"3","key":"2023110711203627500_CIT0014","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1053\/j.gastro.2014.05.008","article-title":"Effects of vedolizumab induction therapy for patients with Crohn\u2019s disease in whom tumor necrosis factor antagonist treatment failed","volume":"147","author":"Sands","year":"2014","journal-title":"Gastroenterology."},{"issue":"9","key":"2023110711203627500_CIT0015","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1007\/s00535-018-1480-0","article-title":"Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease","volume":"53","author":"Schreiber","year":"2018","journal-title":"J Gastroenterol."},{"issue":"2","key":"2023110711203627500_CIT0016","first-page":"75","article-title":"Vedolizumab-induced de novo extraintestinal manifestations","volume":"16","author":"Diaz","year":"2020","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"5","key":"2023110711203627500_CIT0017","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1136\/annrheumdis-2016-210233","article-title":"An induction or flare of arthritis and\/or sacroiliitis by vedolizumab in inflammatory bowel disease: a case series","volume":"76","author":"Varkas","year":"2017","journal-title":"Ann Rheum Dis."},{"issue":"4","key":"2023110711203627500_CIT0018","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s10620-018-4971-1","article-title":"Effects of vedolizumab therapy on extraintestinal manifestations in inflammatory bowel disease","volume":"63","author":"Fleisher","year":"2018","journal-title":"Dig Dis Sci."},{"issue":"4","key":"2023110711203627500_CIT0019","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/apt.14419","article-title":"Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort","volume":"47","author":"Tadbiri","year":"2018","journal-title":"Aliment Pharmacol Ther."},{"issue":"9","key":"2023110711203627500_CIT0020","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1136\/annrheumdis-2016-211011","article-title":"Clinical benefit of vedolizumab on articular manifestations in patients with active spondyloarthritis associated with inflammatory bowel disease","volume":"76","author":"Orlando","year":"2017","journal-title":"Ann Rheum Dis."},{"issue":"Suppl 1","key":"2023110711203627500_CIT0021","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1097\/01.MIB.0000480260.28955.65","article-title":"P-105 The effect of vedolizumab on extraintestinal manifestations in patients with Crohn\u2019s disease in GEMINI 2","volume":"22","author":"Rubin","year":"2016","journal-title":"Inflamm Bowel Dis."},{"issue":"Suppl 1","key":"2023110711203627500_CIT0022","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1093\/ibd\/zaa010.047","article-title":"Effects of vedolizumab on extraintestinal manifestations in \u00adinflammatory bowel disease","volume":"26","author":"Dimopoulos","year":"2020","journal-title":"Inflamm Bowel Dis."},{"issue":"8","key":"2023110711203627500_CIT0023","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1093\/ibd\/izaa293","article-title":"The impact of vedolizumab on pre-existing extraintestinal manifestations of inflammatory bowel disease: a multicenter study","volume":"27","author":"Ramos","year":"2021","journal-title":"Inflamm Bowel Dis."},{"issue":"Suppl 1","key":"2023110711203627500_CIT0024","doi-asserted-by":"crossref","first-page":"S302","DOI":"10.1093\/ecco-jcc\/jjab076.391","article-title":"P266 The impact of vedolizumab and ustekinumab on arthropathy and arthralgia in IBD patients: a real-life multicentric cohort study","volume":"15","author":"Truyens","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2023110711203627500_CIT0025","author":"MedDRA"},{"issue":"Suppl 1","key":"2023110711203627500_CIT0026","doi-asserted-by":"crossref","first-page":"S308","DOI":"10.1093\/ecco-jcc\/jjab076.401","article-title":"P276 Influence of vedolizumab on extraintestinal manifestations in inflammatory bowel disease: a nationwide multicenter study of the GETECCU Eneida registry","volume":"15","author":"P\u00e9rez Galindo","year":"2021","journal-title":"J Crohns Colitis"},{"issue":"Suppl 1","key":"2023110711203627500_CIT0027","doi-asserted-by":"crossref","first-page":"S472","DOI":"10.1093\/ecco-jcc\/jjz203.687","article-title":"P559 Effect of vedolizumab and ustekinumab on articular manifestations in patients with inflammatory bowel disease refractory or intolerant to anti-TNF therapy: an observational prospective study","volume":"14","author":"Britschu","year":"2020","journal-title":"J Crohns Colitis"},{"issue":"Suppl 1","key":"2023110711203627500_CIT0028","doi-asserted-by":"crossref","first-page":"S473","DOI":"10.1093\/ecco-jcc\/jjz203.688","article-title":"P560 Incidence of joint symptoms in patients with inflammatory bowel disease on treatment with vedolizumab","volume":"14","author":"Ruiz-Ramirez","year":"2020","journal-title":"J Crohns Colitis"},{"issue":"Suppl 1","key":"2023110711203627500_CIT0029","doi-asserted-by":"crossref","first-page":"S546","DOI":"10.1093\/ecco-jcc\/jjz203.792","article-title":"P664 The impact of vedolizumab on extra-intestinal manifestations in inflammatory bowel disease patients: a real-life experience of a single-centre cohort","volume":"14","author":"Truyens","year":"2020","journal-title":"J Crohns Colitis"},{"issue":"12","key":"2023110711203627500_CIT0030","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/ecco-jcc\/jjz095","article-title":"Vedolizumab treatment in extra-intestinal manifestations in inflammatory bowel disease: a systematic review","volume":"13","author":"Chateau","year":"2019","journal-title":"J Crohns Colitis"},{"issue":"3","key":"2023110711203627500_CIT0031","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s40265-020-01460-3","article-title":"Vedolizumab and extraintestinal manifestations in inflammatory bowel disease","volume":"81","author":"Hanzel","year":"2021","journal-title":"Drugs."},{"issue":"8","key":"2023110711203627500_CIT0032","first-page":"e17187","article-title":"Extra-intestinal manifestations of inflammatory bowel disease","volume":"13","author":"Sange","year":"2021","journal-title":"Cureus"},{"issue":"3","key":"2023110711203627500_CIT0033","doi-asserted-by":"crossref","first-page":"300","DOI":"10.3109\/00365521.2014.991752","article-title":"Extraintestinal manifestations in Crohn\u2019s disease and ulcerative colitis: results from a prospective, population-based European inception cohort","volume":"50","author":"Isene","year":"2015","journal-title":"Scand J Gastroenterol."},{"issue":"4","key":"2023110711203627500_CIT0034","first-page":"400","article-title":"Long-term efficacy of vedolizumab for ulcerative colitis","volume":"11","author":"Loftus","year":"2017","journal-title":"J Crohns Colitis"},{"issue":"7","key":"2023110711203627500_CIT0035","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1097\/MIB.0000000000001109","article-title":"Anti-TNF treatment for extraintestinal manifestations of inflammatory bowel disease in the Swiss IBD Cohort Study","volume":"23","author":"Vavricka","year":"2017","journal-title":"Inflamm Bowel Dis."},{"issue":"2","key":"2023110711203627500_CIT0036","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1080\/00365521.2017.1416160","article-title":"High treatment persistence rate and significant endoscopic healing among real-life patients treated with vedolizumab - a Finnish Nationwide Inflammatory Bowel Disease Cohort Study (FINVEDO)","volume":"53","author":"Ylisaukko-Oja","year":"2018","journal-title":"Scand J Gastroenterol."},{"issue":"1","key":"2023110711203627500_CIT0037","first-page":"15","article-title":"Effectiveness and persistence of vedolizumab in patients with inflammatory bowel disease: results from the Belgian REal-LIfe study with VEdolizumab (Be-RELIVE)","volume":"83","author":"Reenaers","year":"2020","journal-title":"Acta Gastroenterol Belg."},{"issue":"4","key":"2023110711203627500_CIT0038","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1093\/ecco-jcc\/jjv226","article-title":"Vedolizumab effectiveness and safety over the first year of use in an IBD clinical practice","volume":"10","author":"Vivio","year":"2016","journal-title":"J Crohns Colitis."},{"issue":"6","key":"2023110711203627500_CIT0039","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1007\/s10620-017-4549-3","article-title":"Predictors of clinical response and remission at 1 year among a multicenter cohort of patients with inflammatory bowel disease treated with vedolizumab","volume":"62","author":"Allegretti","year":"2017","journal-title":"Dig Dis Sci."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izad075\/50424386\/izad075.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/29\/11\/1713\/52760834\/izad075.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/29\/11\/1713\/52760834\/izad075.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T06:22:00Z","timestamp":1699338120000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/29\/11\/1713\/7158104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,9]]},"references-count":39,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,5,9]]},"published-print":{"date-parts":[[2023,11,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izad075","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11,1]]},"published":{"date-parts":[[2023,5,9]]}}}